In the ongoing battle against bacterial infections, the development of potent and effective antibiotics remains a top priority for the pharmaceutical industry. Finafloxacin, a significant advancement in fluoroquinolone therapy, represents a crucial tool in this fight. Understanding this API and the critical intermediates required for its synthesis is vital for researchers, formulators, and procurement specialists. This article delves into the world of Finafloxacin and the indispensable role of its key precursor.

Finafloxacin (CAS 209342-40-5), classified as a fluoroquinolone antibiotic, has gained recognition for its unique pharmacological profile. Unlike many of its predecessors, Finafloxacin exhibits enhanced antibacterial activity in slightly acidic environments, a characteristic that makes it particularly effective for certain therapeutic applications, such as treating acute otitis externa. This condition, commonly known as swimmer's ear, can be caused by resistant strains of bacteria like Pseudomonas aeruginosa and Staphylococcus aureus, making an effective antibiotic like Finafloxacin invaluable. Pharmaceutical companies seeking to buy this advanced API need to ensure a reliable supply of its high-quality intermediate.

The synthesis of Finafloxacin relies on a complex series of chemical reactions, with 8-Cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo-3-Quinolinecarboxylic acid serving as a pivotal intermediate. The purity and consistency of this intermediate directly impact the quality and efficacy of the final API. Therefore, sourcing this compound from a reputable supplier is non-negotiable. For those looking for CAS 209342-40-5 price, it's essential to consider the entire value chain, from synthesis to quality assurance.

As a leading manufacturer in the pharmaceutical intermediate space, we understand the critical importance of this compound. We offer high-purity 8-Cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo-3-Quinolinecarboxylic acid, ensuring it meets the stringent requirements for API synthesis. Our commitment is to provide pharmaceutical companies with the materials they need to develop life-saving medications. If you are interested in exploring the purchase of this essential intermediate, we invite you to contact us for detailed specifications and competitive quotations.